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& Summaryhighlights
stablished in Lisbon in 1994, the
European Monitoring Centre for
Drugs and Drug Addiction
(EMCDDA) gathers and
disseminates information on:
- the demand for drugs and measures to
reduce that demand;
- national and European Community
strategies and policies;
- international cooperation and the
geopolitics of the supply of drugs;
- control of trade in narcotic drugs,
psychotropic substances and precursor
chemicals;
- implications of the drugs phenomenon for
producer, consumer and transit countries.
In line with the EMCDDA’s initial priorities,
this report concentrates on what is known
about the extent and nature of the demand for
drugs (epidemiology) in the European Union
and measures to reduce that demand,
respectively the subjects of chapters 1 and 2
in part I. The context for demand reduction
and other anti-drug measures in Europe is
provided largely by the national and European
strategies described in part II.
For this first report especially, it is important
not just to deliver the end results of the
EMCDDA’s information collection
programmes, but also to enable policymakers
at national and European level to understand
the infrastructure on which those results
expert centres which process information from
those sources.
Part III reports on information sources for
epidemiology and demand reduction, and
explores the degree to which the information
held and systems developed by the
EMCDDA’s priority international partners
can help meet the EMCDDA’s objectives.
Part IV describes the nature and capacities of
the National Focal Points which support the
European Information Network on Drugs and
Drug Addiction, then goes beyond these to
survey the drug documentation centres on
which, in turn, many of the Focal Points
depend.
Throughout it is emphasised that this first
report reveals as much (or more) about what
needs to be done to improve the information
infrastructure (especially in terms of
cross-national compatibility) as it does about
the current fruits of that infrastructure. The
EMCDDA and its key international partners,
the National Focal Points, are embarked on a
process that will not quickly or easily reach
the objective of a drug information system fit
to serve not just national, but also European
needs. However, this first report delivers
sufficient substantive information to justify
the task and confirm the promise of the
journey.
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Prevalence & patterns of use
•  The proportion of the general adult
population who say they have tried an
illegal drug typically ranges from about 5-8
per cent in several countries to 11-16 per
cent in several others, but is higher (10 to
20 per cent) among younger adults.
 
•  Much lower percentages admit drug use in
the last 12 months. For cannabis this
ranges from 1 to about 4-5 per cent, but 5
to 15 per cent in younger age groups.
 
•  Cannabis continues to be the most common
illegal drug throughout the European
Union. The most common pattern of use is
occasional or intermittent rather than
frequent.
 
•  Cocaine use is rare but there have been
modest increases in prevalence in most
countries. Typically, use is social and
intermittent. Crack smoking has recently
emerged as a significant problem among
some urban marginalised groups.
 
•  Typically about 1 per cent or less of the
general population have tried heroin.
However heroin-related problems are the
most prominent of all the drugs. The total
number of heroin addicts in the EU could
be between 500,000 and one million.
 
•  Since the late ’80s
amphetamines, ecstasy
and sometimes LSD, have
become more popular
among young people. By
age 18 to 20, in some
countries 3-4 per cent and
in others 9-10 per cent of
young adults have tried amphetamines and
similar proportions have tried ecstasy and
LSD.
 
•  
related deaths in the last half of the 1980s
and in some the total may now again be
increasing.
 
•  Increased misuse of medicines and
problems arising from drug combinations
are reported but generally the main
problem drug for new treatment clients is
heroin; amphetamines are important in
northern Europe.
 
•  Average ages of new treatment clients are
between the early 20s and early 30s and
two-thirds or more are men.
 
•  There are extreme differences in drug-
related HIV and AIDS rates among drug
injectors. The rate of new HIV infections
has been falling but the behaviours that
transmit HIV continue to be practised.
 
•  Since the 1980s most countries have
witnessed rising totals for offences
against the drug laws; drug users
often form 30-40 per cent of the
prison population.
Demand reduction
•  Most EU Member States have increased
their investment in demand reduction and
all agree that demand reduction is a
multidisciplinary, community
responsibility. This
philosophy is matched by
the predominance of
decentralised initiatives.
 
•  Preventing drug use is a
universal priority.
Common across the EU
are approaches which focus on the factors
which lead to drugtaking or protect young
people from drug use, moving the emphasis
from drugs to wider family and social
influences.
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PART I
Demand &
demand reduction
 
·  School programmes are the most
widespread form of primary prevention in
Europe and often a legally required
component of secondary education.
 
 
 
·  Primary prevention seems most effective
when it starts early and continues
seamlessly through to secondary school.
Addressing young people’s attitudes to
drugs and to themselves appears to
improve outcomes. Experts favour
programmes dealing with illegal drugs in the
context of legally available substances and
general health promotion.
 
·  Mass media campaigns raise awareness but
do not of themselves cause behaviour
change or significant shifts in attitude.
Member States which conduct mass media
campaigns often aim to raise awareness or
transmit information.
 
·  The classical treatment chain has given way
to much more flexible and differentiated
services. Treatment now includes a
comprehensive range of community-based
care services which may aim to help drug
users give up drugs and maintain abstinence
and/or to reduce the risks of drug misuse.
 
·  Therapeutic communities are more
common in southern
European countries than
in the north. Programmes have moved
towards shorter stays, greater
professionalism, individualised therapy,
and preparing residents for life after
treatment.
·  There are few consistent studies on
treatment impact. Completing the
programme is the most stable prognostic
factor; the longer abstinence has been
maintained, the more likely it is to
continue.
 
·  Preventing (further) damage among those
who use drugs features in many national
policies. Typically the focus is on reducing
health risks, especially the risk of
contracting HIV and other infections, and
encouraging early entry into treatment.
 
·  Though long-term methadone prescribing is
available in all EU Member States, its scale,
the entry criteria for patients, and the
degree of official regulation, all differ
widely. In several states such prescribing
has recently expanded rapidly.
 
·  Lack of knowledge and confidence often
impedes the involvement of generic
professionals in drug prevention or
treatment, depriving drug users of the range
of general health and welfare services
available to the rest of the population. This
is partly a symptom of the need to develop
professional training programmes in all
Member States.
National
strategies
·  National drug strategies in the EU typically
aim to maintain a balance between policies
to reduce the demand for drugs and those
aimed at reducing supply.
 
·  The fundamental
administrative tasks are to
create structures capable of coordinating
the policies of national ministries, and co-
ordinating the national administration with
those at regional level.
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PART II
Anti-drug
strategies
 
 
·  National policies are increasingly defined
by supranational policies or by a nation’s
obligations under United Nations
conventions. Nevertheless, drug laws vary
considerably across the EU Member
States.
 
·  Drug use is always indirectly prevented by
prohibiting possession but less than half
the EU Member States prohibit it directly.
Some states punish possession for
personal use only by administrative
sanctions.
·  Studying national strategies and laws in the
context of the European Union can help
nations understand how other EU Member
States organise their strategies and widen
perspectives on the policy options
available.
Action taken by the European
Union
·  Since 1987 the European Community as
such has been a party to international
action against drugs.
 
·  Arguments that the new Single Market
demanded a high level of coordination led
to the development of European Action
Plans on Drugs. To underpin these it was
considered essential to set up a European
drugs information centre.
 
·  Entry into force of the Treaty on European
Union in 1993 offered the potential for a
fully integrated approach, resulting in a
new plan for 1995-1999.
 
 
 
·  The two major ways for the European
Union to deal with drugs are firstly in
policy areas where Community institutions
are empowered to represent Member
States, and secondly by cooperation
between Member States. The first includes
public health, money laundering, and
diversion of precursor chemicals, the
second foreign and security policy and
justice and home affairs.
 
·  In 1995 the EU spent 27.9 million ECUs
on anti-drugs action, about half within the
European Union and half outside.
 
·  Both European Council meetings in 1995
addressed the drugs issue, confirming its
high profile. Steps taken that year
significantly advanced coordination and
cooperation among enforcement officials
and placed drugs on the agendas of the
international events in which the
Community participated.
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Epidemiology
·  Epidemiological information of sufficient
quality and relevance enables policymakers
to monitor the impact of their
interventions, identify unmet needs and
of options for responding to those needs,
and allocate resources accordingly.
 
·  As applied to illicit drug use, epidemiology
is a relatively young science; assessing drug
abuse at European level adds a further layer
of complexity, as data needs to be
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·  The data most used to assess drug use are
records of demand for treatment, drug-
related deaths, arrests and drug seizures,
and household and school surveys.
 
·  Surveys are the main tool to assess the
extent of drug use in the general
population. The most common regular
surveys sample the general population and
schoolchildren, but differing methodologies
in Member States mean data is not
comparable.
 
·  Assessing the prevalence of heavier, more
problematic, and less common patterns of
drug use usually entails alternative methods
to study hidden populations.
·  Repeated studies or surveys are valuable
ways to track trends over time. Such trends
can also be tracked by various indirect
indicators based on routine statistics from
welfare or enforcement services.
 
·  Improvements are seen in the quality of
data based on drug-related services or
cases, such as treatment or morbidity;
surveys are generally of good quality but
results cannot easily be pooled or
compared and they tend not to be regularly
repeated, reducing their utility as a means
of monitoring trends.
 
·  Data based on hospital admissions is
frequently available. Of
the diseases related to
drug use, information on
AIDS is most complete.
Diverse definitions and
criteria are used for
collecting data on drug-
related deaths.
 
·  Law enforcement data is available in most
Member States as part of the relevant
overall data collection system; differences
comparability.
 
·  Data compatibility between EU countries
is very limited but a few nuclei can be
identified which could be used as a focus
around which to extend compatibility, both
in terms of indicators and in terms of
Member States.
 
·  The process of exploring similarities and
differences in meanings in different nations
could move on to agreeing where
compatibility can be improved within the
limitations of different policies, laws, and
treatment systems.
 
·  The next step would be the selection of
common definitions and classifications, and
the development of protocols similar to the
Pompidou Group’s treatment demand
protocol.
Demand reduction
·  Constructing an overview is
hindered by the lack of consensus on what
‘demand reduction’ is. Boundaries between
primary prevention, secondary prevention
and treatment are unclear and variously
drawn. This terminology itself is not
universally accepted. A priority task for
the Monitoring Centre is to overcome these
obstacles.
 
·  Information on demand reduction
programmes is difficult to
access. Many involve
disparate authorities and
organisations and are
localised rather than
organised according to a
national agenda, reducing
the incentive to maintain
adequate national
documentation.
 
·  School programmes appear to be the best
documented form of primary drug
PART III
Information
sources
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prevention. Only for these and for general
prevention programmes do more than ten
Member States claim to have centralised
data. Otherwise in no more than six
countries is information said to be
centralised at the country’s Focal Point.
 
·  Information on treatment programmes was
said to be available in just five Member
States, but this low figure may reflect
confusion over the category. Nine Member
States have information on harm reduction
programmes.
 
·  Most Member States either have access to
one or more databases on demand reduction
programmes or are developing one.
Systematic application of quality criteria
before adding information to databases
appears uncommon, but some Member
States are moving to rectify this situation.
 
 
·  The technology via which information
reaches Focal Points is relatively
rudimentary. Most receive most types of
information only on paper.
 
·  There are few reliable evaluations of the
impact of demand reduction programmes.
Programme planners and funders must be
encouraged to incorporate evaluation.
 
·  Rarely is information from different
programmes or countries presented in a
common format which would enable
comparison between approaches.
 
·  Improving information collection requires
upgraded information transmission
systems and comparability requires a
consensus over language.
Exchange between national
and international levels
·  The six priority international partners for
the EMCDDA are the UNDCP, the
Pompidou Group, WHO, Interpol,
Europol, and the World Customs
Organisation.
·  Among these are to be found some of the
world’s most extensive and technologically
advanced information systems on aspects
of drug misuse which could provide key
foci around which to improve the quality
and comparability of epidemiological
information in the European Union.
 
·  However, data collection and analysis
systems differ widely and the interfaces
between them are underdeveloped,
impeding the extent to which they can be
integrated into a comprehensive European
picture.
 
·  In part this is due to the organisations’
differing remits, most confining themselves
to illegal drugs but others treating these in
the context of substance use in general and
health.
 
·  Rather than creating yet another system for
collecting national reports, the EMCDDA
might best contribute by helping to
strengthen and unify Member States’
participation in existing international
systems.
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National Focal Points
·  Focal Points are key information
collection and exchange points in the
European Information Network on Drugs
and Drug Addiction (REITOX), the
network which supports the work of the
EMCDDA.
 
·  Focal Points are almost all expert centres in
their own right. As Focal Points, they are
all still developing structures and functions
to suit emerging needs.
·  However, there is consensus that being a
Focal Point means coordinating their own
national information networks to meet the
EMCDDA’s requirements for a core set of
data, annual national reports on drugs, and
a national information network.
 
·  National networks to support the Focal
Points are varied and in different stages of
development. Most rely on a few key
partners.
 
·  Focal Points outside national
administrations and/or which receive data
mainly in aggregated form have less scope
to influence the quality, presentation and
cross-national compatibility of the
information they handle.
 
·  National Focal Points can
add value to European
drugs initiatives by
helping to upgrade the
cross-EU compatibility
and comparability of
information, harmonising
the collection, storage,
processing and
dissemination of data.
 
·  Arguably, Focal Points are now at the stage
the EMCDDA agree on their roles and
responsibilities and how they should be
supported by European and national
funding.
 Documentation centres
 
·  Each nation of the
European Union has at least the beginnings
of a drug specialist documentation centre.
 
·  There are wide differences in their nature,
size and coverage. Some countries have
large, well-established services but several
are at the initial stages.
 
·  Together their coverage of the subject is
sufficient to provide for a comprehensive
European documentation service on drugs
and drug addiction.
 
·  Electronic access to information is limited
to a minority of Member States.
 
·  Resourcing and levels of communication
technology, professionalism and
standardisation are currently below that
needed to create and sustain an effective
European documentation network.
 
·  Initiatives at European level could free
resources by reducing
overlap and improve
services by encouraging
standardisation and the
networking of
documentation centres
across the European
Union.
 
·  The EMCDDA could act as a European
clearing house for information on research
programmes and initiatives on drugs, in
partnership with the European
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PART IV
Information
structures
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networks and centres.
 
